A reduction treatment agent made of a powder with a particle size within a range of 1500 to 3000 mesh, the powder containing: 20 to 40 parts of a mixed-oxide powder containing magnesium oxide and zinc oxide; and 60 to 80 parts of an organic acid powder containing calcium, ascorbic acid, citric acid and salt. The reduction treatment agent may further contain one to six kinds of metal powder selected from the group of copper, molybdenum, nickel, cobalt, iron and aluminum, each in an amount of one part. Due to this configuration, the reduction treatment agent can be easily mixed with various substances when added to those substances. Even if the target substance is not water, the agent can entirely and uniformly change that substance into a reduced state. Additionally, the reduction treatment agent can act as a surfactant, and therefore, can be used as cosmetics or food.

A reduction treatment agent made of a powder with a particle size within a range of 1500 to 3000 mesh, the powder containing: 20 to 40 parts of a mixed-oxide powder containing magnesium oxide and zinc oxide; and 60 to 80 parts of an organic acid powder containing calcium, ascorbic acid, citric acid and salt. The reduction treatment agent may further contain one to six kinds of metal powder selected from the group of copper, molybdenum, nickel, cobalt, iron and aluminum, each in an amount of one part. Due to this configuration, the reduction treatment agent can be easily mixed with various substances when added to those substances. Even if the target substance is not water, the agent can entirely and uniformly change that substance into a reduced state. Additionally, the reduction treatment agent can act as a surfactant, and therefore, can be used as cosmetics or food.

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. Methods are provided that utilize specific combinations of selected forms selenium. chromium, and molybdenum in combination with fish oil.

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. Methods are provided that utilize specific combinations of selected forms selenium. chromium, and molybdenum in combination with fish oil.

Methods for treatment of chronic liver disease and reversing liver fibrosis are provided. These treatments may be achieved using a medical food composition. The medical food is configured specifically for those having chronic liver disease to provide for specific nutritional requirements caused by the chronic liver disease. Testing of the treated patient allows for tracking of progress and to determine if the liver fibrosis is reversed.

Methods for treatment of chronic liver disease and reversing liver fibrosis are provided. These treatments may be achieved using a medical food composition. The medical food is configured specifically for those having chronic liver disease to provide for specific nutritional requirements caused by the chronic liver disease. Testing of the treated patient allows for tracking of progress and to determine if the liver fibrosis is reversed.

The present specification discloses a composition for external application to skin, containing a tea plant root extract as an active ingredient, for treatment of skin damage caused by fine dust, whereby the expression level of one or more selected from a group consisting of IL-36G (NM_019618), S100A7 (NM_002963), S100A8 (NM_002964) and XDH (NM_000379), which are genes in skin cells the expression level of which is affected by fine dust, is regulated to a normal level.

The present specification discloses a composition for external application to skin, containing a tea plant root extract as an active ingredient, for treatment of skin damage caused by fine dust, whereby the expression level of one or more selected from a group consisting of IL-36G (NM_019618), S100A7 (NM_002963), S100A8 (NM_002964) and XDH (NM_000379), which are genes in skin cells the expression level of which is affected by fine dust, is regulated to a normal level.

The present invention provides a composition containing α-lipoic acid and N-acetylcysteine as active ingredients. The mixed composition of α-lipoic acid and N-acetylcysteine of the present invention can reduce a risk of side effects due to drugs with synergetic effects due to merge administration of two drugs, and can be usefully used for preventing or treating obesity with excellent effects of inhibiting a weight gain compared to each single composition containing α-lipoic acid or N-acetylcysteine.

The present invention provides a composition containing α-lipoic acid and N-acetylcysteine as active ingredients. The mixed composition of α-lipoic acid and N-acetylcysteine of the present invention can reduce a risk of side effects due to drugs with synergetic effects due to merge administration of two drugs, and can be usefully used for preventing or treating obesity with excellent effects of inhibiting a weight gain compared to each single composition containing α-lipoic acid or N-acetylcysteine.